InvestorsHub Logo
Followers 5
Posts 593
Boards Moderated 0
Alias Born 06/11/2010

Re: SvsB post# 5383

Friday, 09/01/2017 6:22:12 AM

Friday, September 01, 2017 6:22:12 AM

Post# of 17454

We rate AUPH Outperform. AUPH is run by a management team with deep experience in lupus nephritis (LN) and corporate development, having executed the ALMS study for CellCept and selling Aspreva and ZymoGenetics to large pharma companies. We project a ~$1.35BN gross market opportunity for voclosporin in the US and a 75% probability of success. Promising Phase 2b results presented in 2016 and updated in early 2017 continue to derisk Voclosporin development. https://www.docdroid.net/CIKaxJ9/aurinia-pharmaceuticals-inc-leerink1.pdf

Posted by ariadinvestor - https://finance.yahoo.com/quote/Auph/community?p=Auph
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AUPH News